This content is machine translated Immuno-oncology Immune checkpoint inhibitors in carcinoma patients – update for the primary care physician. Therapy with anti-PD-1, anti-PDL-1 and anti-CTLA-4 antibodies can also achieve long-term remissions in patients with previously incurable tumor diseases. Whether a carcinoma patient will respond to treatment with checkpoint inhibitors…
View Post 7 min This content is machine translated Triple-negative stage I-III breast carcinoma Attack on an untouchable While targeted therapies are on the rise, there are still tumors that cannot (yet) benefit from this development. One such is triple-negative breast carcinoma. But even here, far from targeted…
View Post 4 min This content is machine translated Non-resectable melanoma New triple therapy improves progression-free survival Both protein kinase inhibitors and ipilimumab/nivolumab combined have better efficacy than their respective monotherapies in patients with non-resectable melanoma. This has been known for some time. An interesting new approach…
View Post 2 min This content is machine translated Small cell lung carcinoma Combined therapy with checkpoint inhibitors is effective Advances in the treatment of small cell lung cancer have been scarce in recent years. Results of second studies now demonstrate a survival advantage for the combination of chemotherapy with…
View Post 2 min This content is machine translated Glioblastoma and brain metastases Immune system can be harnessed A study at the ESMO Symposium in Geneva shows: Brain metastases have dense concentrations of tumor-infiltrating lymphocytes, i.e., an immune-active environment. Second, both primary and secondary brain carcinomas cause high…
